XWBO
MARI
, Last price
EUR
Name
Marinomed Biotech AG
Chart & performance
P/E
—
P/S
—
EPS
10.34
Vol. 1Y
—
Shs. 5Y
4.57%
Rev. 5Y
-1.07%
Div Yld LY
—
Div Yld TTM
—
Revenues
8m
+62.21%
Net income
15m
P
CFO
-5m
L-12.97%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Marinomed Biotech AG is an Austrian-based biopharmaceutical firm dedicated to developing therapeutic solutions for viral and immunological conditions, with its market presence spanning across Austria, other European nations, and globally. Their comprehensive product pipeline includes Budesolv, which addresses allergic rhinitis and autoimmune gastritis, and Tacrosolv, currently undergoing Phase II clinical trials for anterior inflammatory eye diseases. Also featured in their development are Carravin, designed to alleviate nasal congestion, and Inhaleen, which is in Phase I clinical evaluation for viral pneumonia. Additionally, the company offers Carragelose, a range of products like nasal and throat sprays and lozenges, all formulated to combat viral respiratory infections. Established in 2006, the company was initially named Marinomed Biotechnologie GmbH, adopting its current name, Marinomed Biotech AG, in June 2017, and is headquartered in Korneuburg, Austria.
Key people
Simon Nebel
Chairman of the Supervisory Board · since 2017
Andreas Grassauer
Chairman of the Executive Board, Chief Executive Officer · since 2006
Pascal Schmidt
Chief Financial Officer, Member of the Executive Board · since 2018
Helmut Baranyovszki
Head of Finance and Administration, Member of the Extended Management Team
Eva Prieschl-Grassauer
Chief Scientific Officer, Member of the Executive Board · since 2006
Renate Moser
Head of Business Development, Member of the Extended Management Team
Member of the Supervisory Board
Gernot Hofer
Member of the Supervisory Board · since 2018
Karl Lankmayr
Member of the Supervisory Board · since 2017
Headquarters & legal address
Hovengasse 25
Korneuburg, 3 2100
AT
Korneuburg, 3 2100
AT
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||